KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 96 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $33,130,522 | +38.8% | 3,440,345 | +29.8% | 4.68% | +33.1% |
| Q2 2023 | $23,862,537 | +14.5% | 2,651,393 | 0.0% | 3.51% | +13.1% |
| Q1 2023 | $20,839,949 | -3.6% | 2,651,393 | -17.1% | 3.10% | -1.1% |
| Q4 2022 | $21,607,975 | -17.3% | 3,196,446 | +77.6% | 3.14% | -2.0% |
| Q3 2022 | $26,118,000 | +47.5% | 1,800,000 | 0.0% | 3.20% | +19.2% |
| Q2 2022 | $17,712,000 | +85.4% | 1,800,000 | +177.7% | 2.69% | +40.7% |
| Q1 2022 | $9,555,000 | – | 648,269 | – | 1.91% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 589,270 | $8,686,000 | 5.61% |
| GREAT POINT PARTNERS LLC | 874,197 | $12,886,000 | 3.11% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 383,233 | $10,805,000 | 2.44% |
| Frazier Life Sciences Management, L.P. | 1,572,192 | $23,174,000 | 1.98% |
| TANG CAPITAL MANAGEMENT LLC | 648,269 | $9,555,000 | 1.91% |
| Deep Track Capital, LP | 1,729,757 | $25,497,000 | 1.64% |
| Vivo Capital, LLC | 1,533,559 | $22,605,000 | 1.56% |
| Monashee Investment Management LLC | 264,111 | $3,893,000 | 1.13% |
| COMMODORE CAPITAL LP | 312,553 | $4,607,000 | 1.03% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,746,300 | $25,740,000 | 0.79% |